文献速递泌尿男性生殖肿瘤

镭-223联合立体定向消融放疗对比单纯立体定向消融放疗治疗寡转移性前列腺癌的结局:RAVENS II期随机试验

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
PubMed 文献 · J Clin Oncol · 2025-05-07

这项多中心、开放标签II期随机试验将64例复发性寡转移性去势敏感性前列腺癌(omCSPC)骨转移患者1:1随机分配至单纯立体定向消融放疗(SABR)定向治疗组或SABR联合镭-223组,主要终点为复合无进展生存期(PFS)。结果显示两组中位PFS分别为11.8个月和10.5个月(aHR 1.42,95%CI 0.79-2.56,P=0.24),联合镭-223并未延迟疾病进展。

要点

  • 在骨寡转移性去势敏感性前列腺癌中,SABR联合镭-223较单纯SABR未改善无进展生存。
  • ATM、BRCA1/2、RB1或TP53高风险致病突变患者PFS更差(HR 5.95,P=0.003)。
  • T细胞受体独特生产性重排较多与更好的PFS相关(aHR 0.45,P=0.04),与治疗分组无关。

核心结论

  • 在骨转移性寡转移性去势敏感性前列腺癌中,SABR定向治疗联合镭-223并不延迟疾病进展。
  • 研究提供了高风险致病突变特征和T细胞受体库作为接受SABR定向治疗的omCSPC预后生物标志物的证据。

研究设计与样本

  • 研究者发起的多中心、开放标签II期随机对照试验。
  • 纳入复发性omCSPC且至少一个骨转移(常规影像≤3个和/或分子影像≤5个)的男性患者。
  • 按1:1随机分配至单纯SABR定向治疗组(33例)或SABR联合镭-223组(31例),镭-223共六个周期。
  • 主要终点为复合无进展生存期。
  • 2019年8月9日至2023年3月2日期间共随机分配64例患者。

主要发现

  • SABR组中位PFS为11.8个月,SABR联合镭-223组为10.5个月(aHR 1.42,95%CI 0.79-2.56,P=0.24)。
  • SABR联合镭-223组中87%的患者完成了六个周期的镭-223治疗。
  • 7例(11%)患者发生3级治疗相关不良事件(无4级或5级),其中SABR组33例中2例(6%),SABR联合镭-223组30例中5例(17%)。
  • ATM、BRCA1/2、RB1或TP53高风险致病突变患者PFS更差(HR 5.95,95%CI 1.83-19.3,P=0.003)。
  • T细胞受体独特生产性重排较多与改善的PFS相关,且与治疗分组无关(aHR 0.45,95%CI 0.21-0.96,P=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Randomized clinical trials (RCTs) have shown progression-free survival (PFS) benefits of metastasis-directed therapy (MDT) without androgen deprivation therapy for oligometastatic castration-sensitive prostate cancer (omCSPC). Most patients with bone metastatic (BM) omCSPC recur with additional bone disease after MDT. We hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical bone disease and delay progression. METHODS: This is an investigator-initiated, multicenter, open-label phase II RCT. Eligible men with recurrent omCSPC with ≥one bone metastasis (≤three on conventional imaging and/or ≤five on molecular imaging) were randomly assigned (1:1) to stereotactic ablative radiation (SABR) MDT alone or SABR MDT with Ra223 (six cycles). Primary end point was composite PFS. RESULTS: From August 9, 2019, to March 2, 2023, 64 patients were randomly assigned, 33 to SABR MDT and 31 to SABR MDT/Ra223 balancing for key covariates. Most SABR MDT/Ra223 patients (87%) received six cycles of Ra223. The median PFS was 11.8 months with SABR MDT and 10.5 months with SABR MDT/Ra223 (adjusted hazard ratio [aHR], 1.42 [95% CI, 0.79 to 2.56]; P = .24). Seven patients (11%) experienced grade 3 treatment-related adverse events (no grade 4 or 5), 2 of 33 (6%) with SABR and 5 of 30 (17%) with SABR MDT/Ra223. Patients with high-risk (HiRi) pathogenic mutations in ATM, BRCA1/2, RB1, or TP53 had worse PFS (HR, 5.95 [95% CI, 1.83 to 19.3]; P = .003). Greater T-cell receptor (TCR) unique productive rearrangements were prognostic for improved PFS independent of the treatment arm (aHR, 0.45 [95% CI, 0.21 to 0.96]; P = .04). CONCLUSION: Adding Ra223 to SABR MDT in BM omCSPC does not delay progression of disease. We provide evidence for an HiRi mutational signature and TCR repertoire as prognostic biomarkers in omCSPC treated with SABR MDT, highlighting the importance of collecting biological correlates in RCTs for omCSPC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang JH, Sherry AD, Bazyar S, et al. Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. J Clin Oncol. 2025. PMID: 40334149. doi:10.1200/JCO-25-00131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。